European Pharmaceutical Review

NOVEMBER 16, 2023

While Europe has historically been a pioneer in the adoption of biosimilars, a new report by the global initiative Act4Biosimilars has revealed differences country by country, including disparities between Eastern and Western Europe. This is based on research from a report published in April this year by IQVIA.

Biosimilars 110

Biosimilars 110

European Pharmaceutical Review

APRIL 11, 2024

Over the past few years, the biosimilar market has expanded “rapidly” due to these medicines offering a cost-effective alternative to the reference product. As of September 2022, there were around 39 biosimilars approved and 22 marketed, the report stated. million by 2032, at 17.6 percent CAGR between 2023 and 2032.

Biosimilars 105

Biosimilars 105

STAT

AUGUST 30, 2023

government’s initial approach to negotiating drug prices could discourage cheaper biosimilar versions of more complex pharmaceuticals that eat up a high portion of total Medicare spending , Bloomberg Law explains. Amgen and J&J reached an agreement in May to allow a biosimilar for Stelara no later than Jan.

Biosimilars 249

Biosimilars Drug Pricing 249

Safe Biologics

DECEMBER 8, 2022

ASBM Presents at Festival of Biologics 2022 Europe From November 2nd-4th, ASBM representatives participated in the Festival of Biologics 2022 Europe, held in Basel, Switzerland. ASBM Advisory Board Chair Philip Schneider, MS, FASHP, FFIP gave a presentation entitled “Key Factors for Improving Sustainability in Biosimilar Markets”.

Biosimilars 100

Biosimilars Communication Drug Development 100

Safe Biologics

JANUARY 1, 2023

ASBM Adds Module on PBM Practices to OSU College of Pharmacy Biosimilars Course In December, ASBM recorded the seventh and final module in its biosimilar Continuing Education (CE) Course on Biosimilars, presented with the Ohio State University College of Pharmacy. Feldman explains unique features of the U.S. The bifurcated U.S.

Biosimilars 100

Biosimilars Drug Pricing 100

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my nearly 30,000 (!)

Biosimilars 98

Biosimilars 98

European Pharmaceutical Review

AUGUST 4, 2023

According to data and analytics company GlobalData , Boehringer Ingelheim’s Cyltezo has demonstrated the intersection of price and regulation in the biosimilars market. “Of This has developed following numerous adalimumab biosimilar offerings being brought to market. billion in 2022, a product that was launched in 2002.

Biosimilars 97

Biosimilars 97

European Pharmaceutical Review

SEPTEMBER 20, 2022

The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have announced that biosimilar medicines authorised in the European Union (EU) can now be interchanged with their reference medicine or an equivalent biosimilar product. Interchanging biosimilars is an acceptable practise already used by many Member States.

Biosimilars 98

Biosimilars Diabetes 98

Drug Patent Watch

DECEMBER 10, 2024

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

Biosimilars 97

Biosimilars 97

European Pharmaceutical Review

OCTOBER 14, 2022

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. More interchangeable biosimilars are estimated to be approved and launched in the US in the next few years. .”

Biosimilars 97

Biosimilars 97

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Prices are dropping while adoption accelerates.

Biosimilars 98

Biosimilars 98

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Sustainable biosimilar competition in Europe: can it be achieved? Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We

Biosimilars 98

Biosimilars 98

Big Molecule Watch

SEPTEMBER 15, 2023

Generic & Biosimilar Medicines Savings Report highlighting the significant economic contributions of generic and biosimilar medicines. healthcare system, including patients, employers and taxpayers, saved $408 billion in 2022 by using FDA-approved generic and biosimilar drugs, per the AAM’s report. for brands.

Biosimilars 69

Biosimilars Prescription Filling 69

Express Pharma

AUGUST 1, 2023

The potential revenue replacing Humira has resulted in many adalimumab biosimilar offerings being brought forth (currently nine FDA-approved agents), and a rapidly overcrowded market. Against this backdrop, Cyltezo from Boehringer Ingelheim has shown the intersection of price and regulation in the biosimilar market, says GlobalData.

Biosimilars 98

Biosimilars 98

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars 98

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Each exclusion list contains 400 to 500 products.

Biosimilars 98

Biosimilars 98

Drug Channels

APRIL 20, 2022

Click here to see the original post and comments from January 2022. For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars 98

Drug Channels

JANUARY 10, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. I also note some troubling research on the patient impact of exclusions—although much remains unknown.

Biosimilars 98

Biosimilars 98

Drug Channels

SEPTEMBER 13, 2022

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation.

Biosimilars 97

Biosimilars Hospitals 97

Big Molecule Watch

NOVEMBER 14, 2023

District Court for the Northern District of West Virginia, alleging infringement of thirty-eight patents under the BPCIA based on Celltrion’s submission of an aBLA for CT-P42, a proposed biosimilar of EYLEA (aflibercept), and Celltrion’s provision of Notice of Commercial Marketing with respect to the same.

Biosimilars 114

Biosimilars 114

Drug Channels

DECEMBER 12, 2022

Click here to see the original post and comments from September 2022. By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Hospitals 98

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Read on for Steve’s insights. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars 98

Drug Channels

AUGUST 23, 2022

on key specialty pharmacy trends Evidence for biosimilar-to-biosimilar switching Plus, Dr. Glaucomflecken takes on PBMs! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars Specialty Pharmacies 75

pharmaphorum

APRIL 1, 2022

Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko.

Biosimilars 59

Biosimilars Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 59

Big Molecule Watch

APRIL 20, 2023

On March 31, 2023, Mabwell announced that China’s National Medical Products Administration (NMPA) has approved MAILISHU, a denosumab biosimilar, for the treatment of osteoporosis in postmenopausal women at high risk of fracture. MAILISHU was developed by Mabwell’s wholly owned subsidiary, T-Mab.

Biosimilars 72

Biosimilars 72

Drug Channels

OCTOBER 25, 2022

Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Mark Cuban tells ghost stories about PBMs. Walgreens terrifies Wall Street with its 340B losses. Physicians think payers cast evil utilization management spells. d/b/a Drug Channels Institute.

Biosimilars 75

Biosimilars 75

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill. to 1:30 p.m.

Biosimilars 75

Biosimilars 75

Big Molecule Watch

MAY 25, 2023

Today Celltrion announced that the FDA approved its biosimilar product, YUFLYMA (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of HUMIRA. As we previously reported , Celltrion entered into an agreement in April 2022 with AbbVie that would allow Celltrion to market its biosimilar to AbbVie’s HUMIRA product.

Biosimilars 75

Biosimilars 75

Pharma Pathway

DECEMBER 7, 2022

Hetero Limited-Campus Placement Drive for Freshers -Production/ QA/ QC/ R&D On 9th, 13th, 17th, 22nd December 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. Campus Placement Drive for Freshers -Production/ QA/ QC/ R&D On 9th, 13th, 17th, 22nd December 2022.

Biosimilars 87

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 87

Pharma Pathway

SEPTEMBER 16, 2022

Hetero Labs Limited-Campus Placement Drive for Freshers On 17th Sept’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar.

Biosimilars 79

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 79

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices. Special preorder and launch pricing discounts will be valid through March 28, 2022.

Specialty Pharmacies 96

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 96

Pharma Pathway

SEPTEMBER 13, 2022

Hetero Labs Limited-Walk-In Interviews for QA/ Production On 17th Sept’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar.

Biosimilars 80

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 80

Pharma Pathway

SEPTEMBER 21, 2022

Hetero Labs Limited-Walk-In Interviews for EHS- Process Safety Management/ Process Safety Lab On 24th Sept’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. On 24th Sept’ 2022 @ Hetero Labs Ltd. Passout: 2020, 2021, 2022. Job Description.

Biosimilars 83

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 83

Pharma Pathway

DECEMBER 13, 2022

Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC On 14th Dec’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar.

Biosimilars 80

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 80

Pharma Pathway

DECEMBER 3, 2022

Hetero Labs Limited-Walk-In Interviews for Production/ Production Packing/ QA/QC / Engineering On 10th & 11th Dec’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. Date of Interview: 10th & 11th Dec’ 2022. Job Description.

Biosimilars 86

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 86

Pharma Pathway

SEPTEMBER 13, 2022

On 16th Sept’ 2022. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. With more than 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include API’S, generic and biosimilar. On 16th Sept’ 2022 @ Hetero Labs Ltd.

Biosimilars 78

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 78

Pharma Pathway

SEPTEMBER 15, 2022

Walk-In Interview for MSAT & Process Engineering-Injectables On 18th Sept’ 2022. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Date : 18th Sept’ 2022. Reddy’s Laboratories Ltd.-Walk-In Job Description.

Biosimilars 87

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 87